Nanoparticles Navigating the Blood–Brain Barrier: A New Frontier in Neurodegenerative Disease Therapy
Key Insights
Nanoparticle-based drug delivery systems are demonstrating significant potential to cross the blood-brain barrier, a critical obstacle in treating Alzheimer's, Parkinson's, and Huntington's diseases.
Multiple nanoplatform strategies—including receptor-mediated endocytosis, intranasal delivery, photothermal-assisted BBB opening, and biomimetic exosome systems—have shown therapeutic efficacy in preclinical animal models.
Despite promising results, no nanoparticle-based therapies for neurodegenerative diseases have entered Phase III clinical trials, with toxicity concerns, manufacturing complexity, and the gap between animal models and human application remaining major hurdles.
The blood-brain barrier (BBB) remains the single greatest obstacle to effective pharmacological treatment of neurodegenerative diseases. While Alzheimer's disease (search) alone affects 50 million people globally—a figure projected to reach 150 million by 2050—currently approved medications provide only symptomatic relief and fail to halt or reverse disease progression. Now, a comprehensive review published in the International Journal of Nanomedicine systematically maps the landscape of nanoparticle-based strategies designed to overcome this formidable biological barrier, offering a structured framework for advancing these technologies toward clinical application.
The review constructs an analytical framework organized around two core dimensions: "barrier crossing" and "pathological regulation." Unlike previous reviews focused on single diseases or delivery vehicles, this work examines how nanoparticles can not only deliver therapeutic cargo across the BBB but also, in some cases, exert disease-modifying effects through their intrinsic physicochemical properties—such as multi-enzyme activity, ion-binding capacity, or photothermal effects.
The BBB Challenge and Nanoparticle Strategies
The BBB is primarily composed of brain microvascular endothelial cells interconnected via tight junctions and adherens junctions, forming a physical barrier that restricts free exchange between the bloodstream and brain tissue. Disruption of the BBB is a common feature across all neurodegenerative diseases, with chronic neuroinflammation and barrier dysfunction observed in Alzheimer's disease (search), Parkinson's disease (search), amyotrophic lateral sclerosis, and Huntington's disease (search).
Nanoparticles—typically ranging from 1 to 100 nanometers in diameter—cross the BBB through several mechanisms: passive diffusion, carrier-mediated transport, receptor-mediated endocytosis, adsorption-mediated endocytosis, and cell-mediated transport. Receptor-mediated transcytosis, achieved by conjugating targeting ligands to nanoparticle surfaces that bind to receptors such as the transferrin receptor (search) on BBB endothelial cells, represents one of the most common and efficient strategies. Additional approaches include intranasal administration, ultrasound-assisted delivery, and transport via the meningeal lymphatic pathway, all of which can bypass the BBB entirely.
Alzheimer's Disease (search): Multi-Mechanism Nanoplatforms
For Alzheimer's disease (search), the review highlights several innovative nanoplatforms. A modular nanodelivery system (DA-PPHATK@PDA) employs dual targeting modules: one uses an Aβ-peptide to target microglia in an immune-tolerant state, delivering hydroxychloroquine to reprogram metabolic profiles from oxidative phosphorylation to glycolysis and restore Aβ phagocytic capacity; the other uses DAG peptides to target reactive astrocytes and deliver all-trans retinoic acid, inducing astrocyte-to-neuron reprogramming.
Another approach involves transferrin-targeted self-assembled nanoparticles (SANP-TF-TEMNAP) that transport a novel TSPO ligand to the hippocampus and cortex, blocking pro-inflammatory signaling pathways activated by lipopolysaccharide or Aβ pathology. Resveratrol-loaded selenium/chitosan nanoparticles (Res@SeNPs@Res-CS-NPs) improve brain energy metabolism through regulation of dysregulated glycolipid metabolism while inhibiting the JNK/AKT/GSK3β signaling pathway to reduce tau phosphorylation and Aβ aggregation.
Gene therapy applications are also advancing. A biomimetic nanovesicle system based on exosome-liposome hybrid vesicles delivers siRNA targeting BACE1 (search) (siBACE1) alongside a TREM2 (search) expression plasmid (pTREM2), achieving a dual mechanism of "inhibiting Aβ production" and "promoting Aβ clearance." In earlier foundational work, dendritic cell-derived exosomes modified with RVG peptide successfully transported BACE1 siRNA to the mouse brain, resulting in significant reductions in BACE1 mRNA and protein levels, as well as dramatically decreased Aβ levels, with no clear adverse effects.
Photothermal therapy represents another frontier. Nb₂C MXenzyme, a stable neuroprotective platform, uses its photothermal conversion efficiency to raise local temperature to approximately 43°C, reversibly opening the BBB through downregulation of vascular endothelial calmodulin and relaxation of tight junctions. The nanoparticle simultaneously chelates pathologically excess Cu²⁺ and exhibits multi-enzyme activities mimicking superoxide dismutase, catalase, and peroxidase. Treated mice showed significantly reduced Aβ plaque deposition in the hippocampus, suppressed astrocyte and microglia activation, and decreased levels of pro-inflammatory cytokines interleukin-1β and tumor necrosis factor-α.
Parkinson's Disease (search): Targeting Apoptosis and Ferroptosis
For Parkinson's disease (search), human serum albumin-based selenium nanoparticles (HSA/Se NPs) administered orally sequentially cross the intestinal epithelial barrier and the BBB, accumulating in dopaminergic neuron regions of the substantia nigra. These nanoparticles inhibit mitochondrial dysfunction and apoptosis via the Bcl-2-cytochrome C-caspase pathway while simultaneously inhibiting ferroptosis through activation of the GPX4 (search)-SLC7A11-GSH pathway. The dual inhibition of apoptosis and ferroptosis—both core pathological mechanisms underlying progressive dopaminergic neuron loss—resulted in significant restoration of tyrosine hydroxylase-positive neurons and increased dopamine concentrations.
The meningeal lymphatic pathway offers an innovative administration route. Nanoparticles injected subcutaneously into the neck drain to cervical lymph nodes and subsequently enter the brain through meningeal lymphatic vessels, completely bypassing the BBB. IHM NPs administered via this route inhibit RAGE receptor expression on microglia while increasing mature cathepsin D levels in lysosomes, enhancing degradation of α-synuclein aggregates.
Engineered extracellular vesicle-based nanoformulations (EVN) loaded with dihydrotanshinone I (search) and coated with CCR2-rich extracellular vesicles respond to CCL2 gradients released by damaged neurons. The formulation activates the Nrf2-GPX4 (search) signaling pathway, promoting nuclear translocation of Nrf2 and upregulating GPX4 expression to specifically inhibit ferroptosis in microglia, converting them from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype.
Huntington's Disease (search): Metal Nanoparticles and Gene Delivery
For Huntington's disease (search), spherical gold nanoparticles (Au3@PEG1k NP) cross the BBB through active transport by endothelial cells, significantly enhancing oxidative phosphorylation pathways in the brain. These nanoparticles inhibit p38α mitogen-activated protein kinase and pyruvate dehydrogenase kinase 1, suppressing neuroinflammation and restoring oxidative phosphorylation capacity. Separately, citrate-functionalized Mn₃O₄ nanoparticles (C-Mn₃O₄ NPs) efficiently mimic glutathione peroxidase activity, selectively catalyzing the reduction of hydrogen peroxide to water. In HD mouse models, these metal nanoparticles significantly reduced lipid peroxidation, restored antioxidant enzyme activity, and preserved basal ganglia structure and cerebellar Purkinje cells.
A hydrogel system based on self-assembling peptide (Fmoc-DDIKVAV) enables controlled release of AAV-DJ vectors encoding brain-derived neurotrophic factor (BDNF), achieving long-term production and secretion of BDNF protein that protects neurons from excitotoxic injury induced by mutant huntingtin protein.
The Clinical Translation Gap
Despite extensive preclinical success, the review authors emphasize a sobering reality: "no nanomedicines targeting neurodegenerative diseases have entered Phase III clinical trials." The translation of nanoparticle technology remains limited due to insufficient brain targeting in humans, toxicity issues, complex pharmacokinetics and clearance processes, and the difficulty of achieving large-scale production under Good Manufacturing Practice (GMP) standards.
Toxicity concerns are particularly pressing. Cationic nanoparticles of gold and polystyrene have been shown to induce hemolysis and blood clotting, and certain concentrations of both anionic and cationic nanoparticles are toxic to the BBB. The increased reactivity from the large specific surface area of nanoparticles enhances drug delivery efficiency but also increases intrinsic toxicity. Free ions released upon intracellular dissolution of metal oxide nanoparticles such as zinc oxide and iron oxide are associated with their toxic effects. Furthermore, some nanoparticles can cause severe neurotoxicity, including excessive ROS production, release of inflammatory factors, DNA damage, and apoptosis.
The review also notes that fewer than 10% of basic research projects are ultimately translated into clinical applications, and the specialized nature of different nanomaterials—each with distinct mechanisms of action and target sites—requires substantial financial support. Early-stage nanoparticle trials are unlikely to provide benefit to participants, making ethical approval and trial implementation extremely difficult.
A Tiered Advancement Strategy
To address these challenges, the authors propose a pragmatic tiered advancement strategy. First, build upon nanoplatforms based on theoretically well-supported materials such as exosomes and metal nanoparticles, whose relatively mature toxicological and pharmacokinetic data allow faster entry into modified new drug pathways. Second, focus on intranasal nanogel or thermosensitive hydrogel systems that bypass the BBB and offer controllable risks associated with local administration. Third, adopt physical strategies for BBB opening centered on photothermal therapy or ultrasound-assisted methods, using ex vivo interventions to enhance nanoparticle crossing and facilitate efficient drug release while reducing the complexity of nanoparticle design.
The review concludes by calling for uniform standards for nanoparticle production, including mandatory requirements regarding preparation methods, cost, safety, and drug-loading efficiency—essential steps if these promising technologies are to move beyond proof-of-concept and into meaningful clinical application.